Tutti gli studi
ReclutamentoFASE4INTERVENTISTICO

Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis

This study is for adults with a rare condition called idiopathic retroperitoneal fibrosis (IRF), where extra tissue grows behind your tummy organs. We're looking at how best to give a steroid medicine called prednisone. Some patients with IRF respond well to prednisone. Before treatment, patients will have a special scan called a PET/CT. If this scan shows a low level of disease activity, we want to see if they can take prednisone for a shorter time than usual. This study will follow patients for up to 21 months to check if this approach is safe and helps to manage their condition. The aim is to find ways to reduce the amount of time patients need to take strong medications.

A colpo d'occhio

Stato
Reclutamento
Fase
FASE4
Sponsor
Assistenza Pubblica - Ospedali di Parigi
Obiettivo di iscrizione
41
Inizio
25 Nov 2022
Completamento stimato
25 Nov 2028

Di cosa tratta questo studio?

This study is exploring a rare condition called idiopathic retroperitoneal fibrosis (IRF). This is when extra tissue grows behind the organs in your tummy, which can sometimes cause problems. The study focuses on adults who have IRF and have not been treated before, or whose condition has returned. The main medicine we are looking at is a steroid called prednisone, which is often used to treat IRF.

Traditionally, patients with IRF might take prednisone for a long time. However, we're trying to find out if some patients, particularly those whose initial scans show a lower level of disease activity, could benefit from a shorter course of treatment. The study uses a special scan called a FDG-PET/CT, which helps doctors see how active the disease is. If this scan shows a low level of activity at the start, we want to see if reducing the steroid treatment is still effective.

By carefully following patients, this study hopes to understand if stopping prednisone earlier for certain individuals is safe and helps to manage their IRF just as well, without increasing the risk of the condition coming back. This could mean fewer side effects for patients from taking powerful medicines for a long time. The overall goal is to improve how we treat IRF and make life better for those living with the condition.

Punti chiave

  • This study investigates a shorter steroid treatment for specific IRF patients.
  • It uses a special scan (FDG-PET/CT) to guide treatment decisions.
  • Patients will take prednisone, with the dose gradually decreasing.
  • Close monitoring over 21 months by doctors and nurses.
  • Aims to reduce long-term side effects of medication.
  • Puoi smettere di partecipare in qualsiasi momento.

Chi può essere idoneo?

To join this study, you need to be an adult (over 18 years old) with a new diagnosis of idiopathic retroperitoneal fibrosis (IRF), or your IRF has returned and hasn't been treated yet. We'll be looking for specific signs of IRF, such as symptoms like pain or certain blood test results, along with a scan showing the extra tissue around your tummy area.

However, there are reasons why you might not be able to join. For example, if your IRF is caused by something else, like another illness or a medicine you're taking, then this study isn't suitable. We also can't include you if you've had certain serious illnesses recently, like particular infections or cancers, or if you're pregnant or breastfeeding. There are also specific medical conditions and medicines that mean you wouldn't be able to take part because they might interfere with the study or make the treatment unsafe for you.

We'll check carefully during your first visits to make sure the study is a good fit for you and that it's safe for you to take part. It's important that you understand why we ask all these questions.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Hai più di 18 anni?
  2. Do you have new or returning idiopathic retroperitoneal fibrosis (IRF)?
  3. Have you not received treatment for your IRF recently?
  4. Are you able to have CT and PET/CT scans?
  5. Non sei incinta o stai allattando?
  6. Do you not have other serious medical conditions or treatments that could interfere?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to join this study, your journey would start with a detailed check-up. This includes a physical exam, a CT scan of your tummy, and blood and urine tests. Once confirmed you can join, you'll have a special discussion with the study team to answer all your questions, and you'll have at least 30 minutes to think about it before signing any consent forms.

Within a week, you'll have an FDG-PET/CT scan (and a pregnancy test if needed) and some samples collected for further analysis. During the study, you'll take prednisone medicine, starting at a specific dose which would then be slowly reduced over several months. You'll have regular follow-up visits over a total of 21 months. Some visits (at 6, 12, and 15 months) will involve physical checks, assessing your medicines, and blood/urine tests. Other visits (at 9 and 21 months, or if your condition comes back) will include more detailed checks like a CT scan and another FDG-PET/CT scan, as well as the usual blood and urine tests. If the treatment isn't working at 9 months, you might leave the study to receive other care.

Rischi e benefici potenziali

Taking part in a study like this could offer potential benefits, such as very close monitoring of your health by a specialist team and access to treatments under carefully controlled conditions. We are hoping to find out if a shorter course of prednisone could reduce side effects for some patients. However, there are potential risks, as with any medical treatment. Prednisone can have side effects, and while we'll be carefully monitoring you, there's always a chance of unexpected effects or that the treatment might not work as well for you as we hoped. Having several scans and blood tests are also part of the study. You're free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Luoghi (15)

  • Médecine Interne
    Codice postale verificato
    Agen, France· Reclutamento
  • Médecine interne
    Codice postale verificato
    Brest, Francia· Reclutamento
  • Médecine interne et maladies infectieuses - GH Sud Haut Lévêque
    Codice postale verificato
    Bordeaux, Francia· Reclutamento
  • Médecine interne - Ambroise Paré
    Codice postale verificato
    Boulogne-Billancourt, France· Reclutamento
  • Médecine interne - Henri-Mondor
    Codice postale verificato
    Créteil, Francia· Reclutamento
  • Médecine interne et immunologie clinique - Dijon
    Codice postale verificato
    Dijon, Francia· Reclutamento
  • Médecine interne - Lille
    Codice postale verificato
    Lille, Francia· Attivo ma non reclutante
  • Médecine Interne - La Timone
    Codice postale verificato
    Marsiglia, Francia· Reclutamento
  • Médecine interne - Saint Antoine
    Codice postale verificato
    Parigi, Francia· Reclutamento
  • Médecine Interne, Vascularites et Myosites - La Pitié Salpêtrière
    Codice postale verificato
    Parigi, Francia· Reclutamento
  • Médecine interne - Cochin
    Codice postale verificato
    Parigi, Francia· Reclutamento
  • Médecine vasculaire - HEGP
    Codice postale verificato
    Parigi, Francia· Reclutamento

Domande comuni

What is idiopathic retroperitoneal fibrosis (IRF)?

IRF is a rare condition where extra tissue grows behind your tummy organs, which can sometimes cause problems. 'Idiopathic' means we don't know the exact cause.

What is FDG-PET/CT?

It's a special type of scan that helps doctors see how active the disease is in your body by looking at how your cells are using sugar.

What is prednisone?

Prednisone is a steroid medicine commonly used to reduce inflammation and help manage conditions like IRF. It's a powerful medicine.

Per quanto tempo sarò nello studio?

The study will follow you for up to 21 months, with regular check-up and scan visits throughout this time.

Can I leave the study early?

Yes, you can choose to leave the study at any time, for any reason. Your decision will not affect your usual medical care.

Come saperne di più

Karim SACRE

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "Early Discontinuation of Steroid Treatment in Negative FDG-P…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.